Prosecution Insights
Last updated: April 19, 2026

Examiner: BRANDSEN, BENJAMIN MICHAEL

Tech Center 1600 • Art Units: 1623 1693

This examiner grants 61% of resolved cases

Performance Statistics

60.6%
Allow Rate
+0.6% vs TC avg
140
Total Applications
+23.5%
Interview Lift
1323
Avg Prosecution Days
Based on 94 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
20.9%
§102 Novelty
34.2%
§103 Obviousness
24.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18014705 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS Non-Final OA The Regents of the University of California
17904907 COMPOSITION AND METHOD TO PREPARE LONG-ACTING INJECTABLE SUSPENSION CONTAINING MULTIPLE CANCER DRUGS Non-Final OA University of Washington
18001655 THERAPEUTIC TREATMENT USING PROTEIN KINASE C (PKC) INHIBITORS AND CYTOTOXIC AGENTS Non-Final OA Cambridge Enterprise Limited
17620612 METHOD FOR ENRICHING NUCLEIC ACIDS BY SIZE Non-Final OA QIAGEN GmbH
18026009 AUTOPHAGY ACTIVATOR Non-Final OA Resonac Corporation
17791851 NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY Non-Final OA INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
17912805 NRTIS, NRTI METABOLITES, AND NRTI ANALOGS FOR MACULAR DEGENERATION AND VIRAL INFECTIONS Final Rejection University of Virginia Patent Foundation
18229838 SIZE SELECTION PURIFICATION USING A THERMOPLASTIC SILICA NANOMATERIAL Non-Final OA PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17784474 RAPID PRECIPITATION-DRIVEN KILOBASE SIZE SELECTION OF HMW DNA Final Rejection PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17960202 POLYHYDROXYLATED CYCLOPENTANE DERIVATIVES AND METHODS OF USE Non-Final OA Sanegene Bio USA Inc.
18305840 WATER DISPERSABLE FILM-FORMING COMPOSITION Non-Final OA AMOREPACIFIC CORPORATION
18284991 CYTOKINE PRODUCTION SUPPRESSING COMPOSITION CONTAINING D-ALLOSE AS ACTIVE COMPONENT, AND METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH CYTOKINE OVERPRODUCTION USING SAME Non-Final OA SETOLAS HOLDINGS, INC.
18560456 APPLICATION OF ALGINATE OLIGOSACCHARIDES Non-Final OA HAITANG (JIANGSU) BIOTECHNOLOGY COMPANY, LTD.
17998030 Tricyclic heterocycles Final Rejection Cancer Research Technology Ltd.
18023359 DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR Non-Final OA JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
18288402 SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD Non-Final OA BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
18552139 COMPOSITIONS COMPRISING TOPIRAMATE FOR TREATING DERMATOLOGICAL CONDITIONS Non-Final OA Sabina GLOZMAN
18550853 Prevention and Treatment of Periodontal and Peri-Implant Disease Non-Final OA LABRIDA AS
18255703 HUMAN MILK OLIGOSACCHARIDES FOR USE IN SUPPORTING MATURATION OR IMPROVEMENT OF SLEEPING PATTERNS Non-Final OA GLYCOM A/S
18006479 AMINOACIDS FOR TREATMENT OF NEUROLOGICAL DISORDERS Non-Final OA ScandiBio Therapeutics AB
17633693 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE Non-Final OA Metro International Biotech, LLC
18000200 NUCLEIC ACID EXTRACTION METHOD AND APPLICATION Non-Final OA NUHIGH BIOTECHNOLOGIES CO., LTD.
17785711 CROSS-LYNKED HYALURONIC ACID SYNTHESIS PROCESS Non-Final OA ISTITUTO GANASSINI S.P.A. DI RICERCHE BIOCHIMICHE
17832165 Methods of Use of Glucosamine for Increasing Nitrogen Retention Final Rejection TSI Bioproducts (Xuzhou) Co., Ltd.
17769522 CYCLODEXTRIN-BASED GAMMALINOLENIC ACID FORMULATION FOR TREATMENT OF BRAIN CANCER Non-Final OA SEFACOR INC.
17624625 TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY Non-Final OA Tambo, Inc.
17623554 INHALABLE COMPOSITION COMPROMISING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS Non-Final OA AQUILON PHARMACEUTICALS SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month